L. Gaster

发表

Inhibition of Transforming Growth Factor (TGF)- 1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF- Type I Receptor Kinase Activity: SB-431542

B. Olson, N. Laping, J. Fornwald, 2002 .

The effects of SB 204070, a highly potent and selective 5‐HT4 receptor antagonist, on guinea‐pig distal colon

G. Kennett, G. Sanger, L. Gaster, 1994, British journal of pharmacology.

4-(6-Methoxy-2-naphthyl)butan-2-one and related analogues, a novel structural class of antiinflammatory compounds.

L. Gaster, A. W. Lake, A. C. Goudie, 1978, Journal of medicinal chemistry.

Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.

D. Middlemiss, S. Lightowler, S. Bromidge, 2000, Journal of medicinal chemistry.

4-(6-METHOXY-2-NAPHTHYL)BUTAN-2-ONE AND RELATED ANALOGS, A NOVEL STRUCTURAL CLASS OF ANTIINFLAMMATORY COMPOUNDS

L. Gaster, A. W. Lake, A. C. Goudie, 1979 .

Increased defaecation caused by 5-HT4 receptor activation in the mouse.

M. I. Smith, G. Sanger, L. Gaster, 1996, European journal of pharmacology.

(1-Butyl-4-piperidinyl)methyl 8-amino-7-chloro-1,4-benzodioxane-5-carboxylate hydrochloride: a highly potent and selective 5-HT4 receptor antagonist derived from metoclopramide.

F. King, S. Starr, P. Wyman, 1993, Journal of medicinal chemistry.

Evidence for a molecular mechanism of teratogenicity of SB-236057, a 5-HT1B receptor inverse agonist that alters axial formation.

M. Welsh, P. Wier, L. Gaster, 2004, Birth defects research. Part A, Clinical and molecular teratology.

SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.

A. Reith, C. Hill, G. Inman, 2002, Molecular pharmacology.

Serotonin 5‐HT3 and 5‐HT4 receptor antagonists

F. King, L. Gaster, F D King, 1997, Medicinal research reviews.

Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5).

Ruth Lehr, B. Olson, N. Laping, 2002, Journal of medicinal chemistry.

N-[(1-butyl-4-piperidinyl)methyl]-3,4dihydro-2H-[1,3]oxazino[3,2- a]indole10-carboxamide hydrochloride: the first potent and selective 5-HT4 receptor antagonist amide with oral activity.

F. King, P. Wyman, G. Sanger, 1995, Journal of medicinal chemistry.

Antagonism by SB 204070 of 5‐HT‐evoked Contractions in the Dog Stomach: an In‐vivo Model of 5‐HT4 Receptor Function

M. I. Smith, S. Bingham, L. Gaster, 1995, The Journal of pharmacy and pharmacology.

Overview Central & Peripheral Nervous System: 5-HT4 receptor antagonists

G. Sanger, L. Gaster, 1994 .

(+/-) 3-Amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole: a conformationally restricted analogue of 5-carboxamidotryptamine with selectivity for the serotonin 5-HT1D receptor.

A. Brown, A. A. Parsons, F. King, 1993, Journal of medicinal chemistry.

Azabicyclic indole esters as potent 5-HT4 receptor antagonists.

F. King, P. Wyman, L. Gaster, 1996, Bioorganic & medicinal chemistry.

3,4-Dihydro-2H-benzoxazinones are 5-HT(1A) receptor antagonists with potent 5-HT reuptake inhibitory activity.

D. Middlemiss, C. Scott, G. W. Price, 2005, Bioorganic & medicinal chemistry letters.

8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.

D. Middlemiss, C. Scott, G. W. Price, 2005, Bioorganic & medicinal chemistry letters.

SB-204070: 5-HT4 receptor antagonists and their potential therapeutic utility

G. Sanger, L. Gaster, 1994 .

SB‐224289–a novel selective (human) 5‐HT1B receptor antagonist with negative intrinsic activity

D. Middlemiss, C. Scott, G. W. Price, 1998, British journal of pharmacology.